The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
| Study Title | A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects with Cystic Fibrosis Aged 18 Years or Older (CHOICES) |
|---|---|
| Study Drug | dirocaftor/posenacaftor/nesolicaftor |
| Type of Study Drug | CFTR Modulation |
| Study Phase | 2b |
| Study Sponsor | University Medical Center Utrecht |
| Link in registry(ies) | https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-500410-26-01 |
| Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
| Age | Adult patients |